Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our work has generated a broad, proprietary portfolio of programs with the potential to provide profound patient benefit, including our sickle cell disease program, FT-4202, and our metastatic, castration-resistant prostate cancer program, FT-7051. Click to visit our booth.